Roche, Atea Pharmaceuticals partner on COVID-19 oral treatment

By Jenni Spinner

- Last updated on GMT

(vladans/iStock via Getty Images Plus)
(vladans/iStock via Getty Images Plus)

Related tags Roche Antivirals Clinical trials COVID-19 Coronavirus Virus

The two companies are working together to develop AT-527, an orally administered, direct-acting antiviral therapy for patients diagnosed with COVID-19.

Roche and Atea Pharmaceuticals are collaborating toward the development, manufacture and distribution of AT-527, Atea’s investigational oral, direct-acting antiviral (DAA). The treatment, currently in Phase II trials, is intended for use in patients both hospitalized and those being treated outside of a hospital setting.

According to the companies, if approved the drug will be the first novel oral antiviral used to treat COVID-19 patients. Additionally, the treatment has the potential to be used in post-exposure, prophylactic applications.

A spokesperson with Roche told us the AT-527 holds potential as a possible solution to treat people with the virus.

“Atea’s AT-527 is a promising oral antiviral with potential for treating COVID-19, and we look forward to collaborating with Atea to investigate AT-527’s potential and to bring this potential medicine to patients as soon as possible should it prove safe and effective​,” they said.

If approval is achieved, Atea will distribute AT-527 inside the US; Roche will be responsible for global manufacturing and distribution outside the US.

AT-527, which acts by blocking the viral RNA polymerase enzyme needed for viral replication, is being studied in a Phase II trial for patients hospitalized with moderate COVID-19. A Phase III trial, anticipated to start in early 2021, will examine potential use in patients outside of the hospital setting.

"The ongoing complexities of COVID-19 require multiple lines of defense; by joining forces with Atea, we hope to offer an additional treatment option for hospitalized and non-hospitalized COVID-19 patients, and to ease the burden on hospitals during a global pandemic,​" said Bill Anderson, Roche CEO.

The Roche spokesperson told Outsourcing-Pharma the company is seeking multiple opportunities and partners to help discover COVID-19 treatments, including the AT-527 partnerhsip.

This collaboration demonstrates our unwavering commitment to look at all options to help more people during this pandemic. We believe that our long-standing global development experience, our technical expertise and manufacturing capabilities as well as our global reach, combined with Atea’s potential treatment option, could have a positive impact on public health in the midst of this pandemic​,” they told us.

We are very pleased to enter into this collaboration with Atea as a first step in a journey to bring an outpatient treatment option to patients with COVID-19 as quickly as possible​,” the spokesperson added.

Related news

Show more

Related products

show more

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

2023 State of Clinical Trial Technology Report

2023 State of Clinical Trial Technology Report

Florence Healthcare | 01-Mar-2023 | Insight Guide

Discover the trends shaping clinical trial technology in 2023, from Site Enablement to eISFs, integrations, and site-sponsor collaboration. This report...

Related suppliers

Follow us


View more